Population pharmacokinetics of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients with advanced solid tumors.

@article{Eldon2011PopulationPO,
  title={Population pharmacokinetics of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients with advanced solid tumors.},
  author={M. Eldon and U. Hoch},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={2598}
}
  • M. Eldon, U. Hoch
  • Published 2011
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2598 Background: NKTR-102 demonstrates significant anti-tumor activity with a tolerable toxicity profile in pts with platinum-resistant/refractory ovarian or metastatic breast cancers. NKTR-102 is a novel topoisomerase I inhibitor that uses Nektar's proprietary polymer conjugation to improve the PK of its active metabolite SN38 resulting in significantly reduced Cmax and sustained exposure throughout the dosing interval. METHODS NKTR-102 was administered as a 90-min IV inf. to 94 pts: 76 pts… CONTINUE READING
    View on PubMed
    doi.org
    2 Citations
    Methods Citations
    1
    2 Citations
    Citation Type

    Citation Type

    Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors
    • 2
    • PDF
    Advances in Delivery of Irinotecan (CPT-11) Active Metabolite 7-Ethyl-10-Hydroxycamptothecin.
    • 6